Regulatory Considerations and Strategies for Drug Repositioning

Author:

Phelps Kenneth V.1

Affiliation:

1. One East 4th Street, Suite 1400CincinnatiOH 45202USAkphelps@camargopharma.com

Abstract

The 505(b)(2) pathway is used to obtain U.S. Food and Drug Administration approval of changes to existing drugs based in whole or in part on public data. This chapter identifies sources of public data and how it can be used in lieu of sponsor-conducted studies. Examples are presented to illustrate a broad range of improvements that can be made to an existing drug under 505(b)(2) as well as the scope of development requirements that can range from simple bioequivalence studies to more complete Phase 2/Phase 3 clinical programs. Patents and market exclusivity are discussed as a means to improve the return on investment needed to encourage the development of these important drug products.

Publisher

The Royal Society of Chemistry

Reference48 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3